Nivolumab: all 1,111 studies that test it
Page 11 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerCompletedNCT03162731Early Phase 1
- Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsActive, not recruitingNCT03155061Phase 1
- Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWithdrawnNCT03149159Phase 2
- Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell TransplantationStatus unknownNCT03146468Phase 2
- A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver CancerCompletedNCT03143270Early Phase 1
- Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
- Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Active, not recruitingNCT03134118Phase 2
- Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and NeckCompletedNCT03132038Phase 2
- SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsWithdrawnNCT03126461Phase 2
- A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2
- Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerWithdrawnNCT03121417Phase 2
- A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03119428Phase 1
- Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03110978Phase 2
- Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyTerminatedNCT03106610Phase 1
- Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerActive, not recruitingNCT03104439Phase 2
- Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginTerminatedNCT03100006Phase 1/2
- Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaActive, not recruitingNCT03097939Phase 2
- BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerCompletedNCT03083691Phase 2
- CheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaCompletedNCT03063450Phase 3
- Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureActive, not recruitingNCT03061539Phase 2
- Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaTerminatedNCT03059147Phase 1
- Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2
- A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWithdrawnNCT03048136Phase 3
- Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)Status unknownNCT03040791Phase 2
- Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular CarcinomaCompletedNCT03033446Phase 2
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseActive, not recruitingNCT03025256Phase 1
- Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation LoadsWithdrawnNCT03023904Phase 2
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaWithdrawnNCT03014804Phase 2
- Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenCompletedNCT03013335Phase 2
- Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 2
- Study of Adjuvant ONO-4538 With Resected Gastric CancerCompletedNCT03006705Phase 3
- Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2
- ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaCompletedNCT03003637Phase 1/2
- A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ CancerCompletedNCT02999295Phase 1/2
- Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersTerminatedNCT02992964Phase 1/2
- Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal CancerTerminatedNCT02991196Phase 1
- Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic MalignanciesTerminatedNCT02985554Phase 1
- Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaCompletedNCT02983006Phase 1
- A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaStatus unknownNCT02982486Phase 2
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
- Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesCompletedNCT02978404Phase 2
- Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2
- Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
- Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCompletedNCT02966548Phase 1
- Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)WithdrawnNCT02962804Phase 2
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease ControlTerminatedNCT02959554Phase 2
- CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingNCT02955290Phase 1/2
- Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02950038Phase 2
- Study to Nivolumab Following Preoperative ChemoradiotherapyStatus unknownNCT02948348Phase 1/2
- Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerCompletedNCT02947386Phase 1
- Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsCompletedNCT02946671Phase 1
- Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02944396Phase 1
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaActive, not recruitingNCT02940301Phase 2
- Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersCompletedNCT02923934Phase 2
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaActive, not recruitingNCT02914405Phase 1
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2
- Nivolumab in Relapsed Pediatric Solid TumorsStatus unknownNCT02901145Phase 1/2
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerCompletedNCT02897765Phase 1
- Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantTerminatedNCT02846376Phase 1
- Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT02845323Phase 2
- Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasCompletedNCT02829931Phase 1
- Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02812667Phase 1
- Nivolumab Plus Radiotherapy in Advanced MelanomaCompletedNCT02799901Phase 2
- Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1CompletedNCT02775292Phase 1
- Study of ONO-4538 in Gastric CancerCompletedNCT02746796Phase 2/3
- SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or SpineCompletedNCT02716948Phase 1
- Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsCompletedNCT02716272Phase 2
- Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaCompletedNCT02652455Early Phase 1
- Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent GlioblastomaTerminatedNCT02648633Phase 1
- Vigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerWithdrawnNCT02639234Phase 2
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
- Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung CancerTerminatedNCT02635061Phase 1
- Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2
- Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabCompletedNCT02628574Phase 1
- Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2
- Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesCompletedNCT02626065Phase 4
- Nivo/Ipi Combination Therapy in Symptomatic Brain MetastasesTerminatedNCT02621515Phase 2
- Combination of Interferon-gamma and Nivolumab for Advanced Solid TumorsCompletedNCT02614456Phase 1
- Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02595944Phase 3
- Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryTerminatedNCT02595918Phase 1
- ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02582125Phase 2
- Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell CarcinomaCompletedNCT02575222Phase 1
- Neoadjuvant Nivolumab in GlioblastomaCompletedNCT02550249Phase 2
- Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
- Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDCompletedNCT02523313Phase 2
- A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and NivolumabCompletedNCT02518958Phase 1
- Nivolumab in Patients With Recurrent Malignant MesotheliomaCompletedNCT02497508Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02453620Phase 1
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasActive, not recruitingNCT02451982Phase 2
- A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)TerminatedNCT02446860Phase 2
- A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
- Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT02393794Phase 1/2
- Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
- HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1